A series of benz [f ]indole-4,9-diones, based on the antitumor activity of 1,4-naphthoquinone, were synthesized and evaluated for their cytotoxic activity in cultured human cancer cell lines A549 (lung cancer), Col2 (colon cancer), and SNU-638 (stomach cancer), and also for the inhibition of human DNA topoisomerases I and II activity in vitro. Several compounds including 2-amino-3-ethoxycarbonyl-N-methyl-benz[f ]indole-4,9-dione showed a potential cytotoxic activity judged by IC 50 º20.0 mg W ml in the panel of cancer cell lines. Especially, 2-hydroxy-3-ethoxycarbonyl-N-(3,4-dimethylphenyl)-benz[f ]indole-4,9-dione had potential selective cytotoxicity against lung cancer cells (IC 50 ＝0.4 mg W ml)) compared to colon (IC 50 À20.0 mg W ml) and stomach (IC 50 À20.0 mg W ml) cancer cells. To further investigate the cytotoxic mechanism, the eŠects of test compounds on DNA topoisomerase I and II activities were used. In a topoisomerase I-mediated relaxation assay using human placenta DNA topoisomerase I and supercoiled pHOTI plasmid DNA, 2-amino-3-ethoxycarbonyl-N-(4-‰uorophenyl)-benz[f ]indole-4,9-dione had the most potent inhibitory activity among the compounds tested. However, most of the compounds showed only weak inhibition of the DNA topoisomerase II-mediated KDNA (Kinetoplast DNA) decatenation assay, except for 2-amino-3-ethoxycarbonyl-N-(4-methylphenyl)-benz[f ]indole-4,9-dione and 2-amino-3-ethoxycarbonyl-N-(2-bromoehtyl)-benz[f ]indole-4,9-dione with a moderate inhibitory activity. These results suggest that several active compounds had relatively selective inhibitory activity against toposiomearse I compared to toposiomerase II. No obvious correlation was observed between the cytotoxicity of the individual compound and the inhibitory activity of DNA relaxation and decatenation by topoisomerase I and II, respectively, in vitro.
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Key words: topoisomerase I and II; benz[f ]indole-4,9-diones; cytotoxicity 1,4-Naphthoquinone derivatives with an amino group at the 2-position have been reported to have good antineoplasmic, 1, 2) carcinostatic actions 3) and bacterial growth inhibition. 4) Based on the cytotoxic potential of 1,4-naphthoquinone derivatives, in our continuing eŠorts to develop novel antitumor agents, we have been synthesized benz[f ]indole-4,9-dione analogs, 5) heterocyclic pyrrole ring derivatives attached to 1,4-naphthoquinone. 6) In this study we evaluated the cytotoxic potential of additional benz[f ]indole-4,9-dione analogs in cultured human solid tumor cell lines including human lung (A549), colon (Col2), and stomach (SNU-638) cancer cells. Further, a variety of antitumor agents currently used in chemotherapy or evaluated in clinical trials are known to inhibit DNA topoisomerase I (topo I) or II (topo II). DNA topoisomerases are enzymes that catalyze the passage of individual DNA strands (type I) or double helices (type II) through one another, which is manifested in the interconversion between topological isomers of DNA. 7) These enzymes have important roles in replication, recombination, transcription, chromosome condensation, and the maintenance of genome stability, 8) and hence are good targets for antineoplastic drugs.
9) The antitumor drugs camptothecin, doxorubicin, and etoposide are representative topo I or topo II inhibitors. Therefore, in this study, to investigate one possible mechanism of action of the cytotoxic activity of benz[f ]indole-4,9-dione analogs, we evaluated their ability to inhibit topo I or topo II activities with DNA relaxation and a DNA decatenation assay, respectively. We report here that benz[f ]-indole-4,9-dione analogs show potential cytotoxicity against cancer cell lines with topo I or II inhibitory activity. 10) The result was expressed as a percentage, relative to solvent-treated control incubations, and the IC50 values were calculated using non-linear regression analysis (percent survival versus concentration).
Materials and Methods
Relaxation assay by topoisomerase I. For the measurement of topoisomerase I catalytic activity, an assay was done using supercoiled pHOT1 DNA as a substrate according to the protocol provided by TopoGEN, Inc. (Columbus, USA). Supercoiled (Form I) plasmid substrate DNA was used in a reaction volume of 20 ml containing the following: 10 mM Tris-HCl, pH 7.9, 1 mM ethylene diamine tetraacetic acid (EDTA), 150 mM NaCl, 0.1z bovine serum albumin (BSA), 0.1 mM spermidine, 5z glycerol, and 1 unit of puriˆed human topoisomerase I (TopoGEN, Inc.). The appropriate inhibitor was added as indicated, and the reaction was started by the addition of the enzyme. After 10 minutes of incubation at 379 C, the reaction was stopped by addition of 5 ml of stop buŠer containing the loading dye (1z sarkosyl, 0.025z bromphenol blue, 5z glycerol), and then the reaction mixture was analyzed on a 1z agarose gel by running at 40 V for 3.5 hrs in TBE buŠer (89 mM Tris, 89 mM borate, 2 mM Na-EDTA, pH 8.3). Gels were stained with SYBR Green I (Molecular Probes, Eugene, OR), and observed under UV illumination. For the quantitative determination of topo I activity, photographic negatives were densitometrically scanned using AlphaImager 2200 (AlphaEase version 5.5). The inhibition of topo I was calculated from the equation: z Inhibition＝[Intensity of sample-treated DNA W Intensity of vehicletreated control DNA]×100.
KDNA decatenation activity of topoisomerase II. The topoisomerase II assay was done by the protocol provided by TopoGEN, Inc. The total reaction volume of the topoisomerase II-mediated cleavage reaction wasˆxed at 20 ml. Brie‰y, assay buŠer [50 mM Tris-HCl, pH 8, 120 mM KCl, 10 mM MgCl2, 0.5 mM ATP, 0.5 mM dithiothreitol, 30 mg W ml bovine serum albumin (BSA)] containing 200 ng of KDNA (TOPOgen), and a solution of the test drugs were added to one unit of the human recombinant topoisomerase II (the amount of enzyme which resulted in the complete decatenation of 200 ng of KDNA). After 10 minutes of incubation at 379 C, the reaction was stopped by addition of 5 ml of stop buŠer containing the loading dye (1z sarkosyl, 0.025z bromphenol blue, 5z glycerol), and then the reaction mixture was analyzed on a 1z agarose gel by running at 40 V for 3.5 hrs in TBE buŠer (89 mM Tris, 89 mM borate, 2 mM Na-EDTA, pH 8.3). Gels were made visible as described above for the relaxation assay. Gels were photographed, and remaining KDNA from photographic negatives was scanned and calculated the inhibition activity as mentioned above.
Results

Cytotoxic activity of benz[ f ]indole-4,9-dione derivatives in cultured human cancer cells
The cytotoxic potential of benz[f ]indole-4,9-dione analogs was tested in three cultured human cancer cell lines A549 (lung), Col2 (colon), and SNU-638 (stomach), by a colorimetric SRB protein dye staining method. As a result, several compounds showed potential cytotoxicity, as shown in Table 1 . Especially, compound 6 [2-amino-3-ethoxycarbonyl-Nmethyl-benz[f ]indole-4,9-dione] showed the most potential cytotoxic activity in the range of IC50 with 0.1¿0.5 mg W ml. In addition, compound 13 [2-hydroxy-3-ethoxycarbonyl-N-(3,4-dimethylphenyl)-benz[f ]indole-4,9-dione] had potential selective cytotoxicity against lung cancer cells (IC50＝0.4 mg W ml)) compared to colon (IC50À20.0 mg W ml) and stomach (IC50À20.0 mg W ml) cancer cells. These active compounds were comparable in cytotoxic potential with the positive compounds ellipticine and doxorubicin in the IC50 range of 0.2¿0.5 mg W ml.
EŠects of benz[ f ]indole-4,9-dione derivatives on topoisomerase I-induced DNA relaxation
To investigate whether benz[f ]indole-4,9-dione mediated cytotoxicity is related to topoisomerase activity, the catalytic activity of topo I was measured using the relaxation assay. As illustrated in Fig. 1 (A  and B) , supercoiled pHOT1 DNA was relaxed by incubation with topo I (Lane 2). In the initial test of compounds at a concentration of 100 mg W ml, compounds 11 and 12 potently inhibited DNA relaxation induced by topo I with 67.8 and 58.7z compared to control DNA, respectively ( Table 2 ). The inhibitory activity by compounds 11 and 12 was much more potent than that of camptothecin at 100 mM (Fig. 1B) .
EŠects of benz[ f ]indole-4,9-dione derivatives on topoisomerase II-induced DNA decatenation
The decatenation assay is speciˆc for measuring topo II activity because it is based on the conversion of catenated DNA to its decatenated form, which requires DNA double strand breakage followed by strand rotation and ligation activities uniquely done by topo II.
11) The removal of these KDNA by the enzyme can be seen in agarose gels. In addition, with respect to topo II, the decatenation of KDNA was induced by topo II, and which was inhibited by treatment with etoposide (VP16, 100 and 200 mM as a positive control) as shown in Fig. 2 . To further elucidate the mechanism of action of test compounds for cytotoxicity, topo II-mediated DNA decatenation activity was evaluated. When tested at a concentration of 50 mg W ml, most of the test compounds were weakly inhibitory (Table 2 ), but compounds 5 and 12 were found to moderately inhibit the conversion of KDNA to the decatenated form ( Fig. 3A and 3B) . 
Discussion
In our continuous eŠorts to develop novel antitumor agents, we designed and synthesized a series of 15 benz[ f ]indole-4,9-dione analogs, based on the antitumor activity of 1,4-naphthoquinones. Primarily, the cytotoxic eŠects of the compounds were measured by the SRB protein staining method in cultured human lung (A549), colon (Col2), and stomach (SNU-638) cancer cells. As shown in Table 1 , among the compounds tested, compound 6 [2-amino-3-ethoxycarbonyl-N-methyl-benz[f ]indole-4,9-dione] showed the most potential cytotoxic activity and was comparable with the positive antitumor agents ellipticine and doxorubicin in the range of IC50 with 0.1¿0.5 mg W ml. In addition, compound 13 [2-hydroxy-3-ethoxycarbonyl-1-(3,4-dimethylphenyl)-benz[f ]indole-4,9-dione] had a potential selective cytotoxicity against lung cancer cells (IC50＝0.4 mg W ml)) compared to colon (IC50À20.0 mg W ml) and stomach (IC 50 À20.0 mg W ml) cancer cells, and also compound 15 [1-ethoxycarbonyl-naphthoquinone-[2,3-d]indolizidine-6,11-dione] was relatively selective for stomach cancer cells. Further studies on these compounds showing selectivity against cancer cell lines might be valuable to identify the mechanism of action. In terms of structure-activity relationships (SAR), the introduction of bulky groups in the Nposition (R2), as exempliˆed with phenyl-analogs, generally reducing cytotoxicity, but substitution with short chain or small molecules including methyl (6), hydroxyethyl (4), hydroxypropyl (10) , and bromoethyl (12) groups potentiated the cytotoxic activity. The selective cytotoxicity of compound 13 with a phenyl analog against human lung cancer cells seems to be exceptional in terms of SAR in this study. Therefore, the steric hindrance and bulkiness around the N-position might be considerable factors in the design of benz[f ]indole-4,9-dione analogs for antitumor agents. In addition, on the basis of intercalating eŠects of heterocyclic quinones on DNA, to investigate whether the cytotoxicity mediated by benz[f ]indole-4,9-dione analogs is related to topoisomerase activity, the catalytic activity of topo I and II were studied as one possible mechanism of action. Topo I is an enzyme that catalyses an ATPindependent relaxation of DNA supercoils by transiently breaking and resealing (religation) singlestranded DNA, allowing the passage of the other strand through the nick, and changing the linking number by one unit.
12) The antitumor drug camptothecin speciˆcally targets topoisomerase I, 13) stabilizing cleavable complexes through inhibition of the religation step. 14) Much research eŠort has been devoted to discovering new drugs targeting this important enzyme, 15) but no major new chemical family with clinical potential speciˆcally acting on topoisomerase I has yet been identiˆed. Topo II is also an important nuclear enzyme controlling DNA topology through catalysis of a transient breakage of double-stranded DNA in an ATP-dependent fashion, allowing for the passage of double-stranded DNA followed by a resealing of the DNA. 15) Relaxation of DNA supercoils by topo II is considered crucial to its role in DNA replication and in transcription and, furthermore, topo II plays a critical role in chromosome condensation and separation during mitosis, and in the attachment of DNA loops to the nuclear matrix and chromosomal scaŠold. 16) Based on this information, we evaluated the benz[f ]indole-4,9-dione analogs for the catalytic activity of topo I and II. With respect to topo I, topo I induced the relaxation of supercoiled DNA. In this case, compounds 11 and 12 had the strongest inhibitory activity, giving 67.8 and 58.7z inhibition at 100 mg W ml, and were comparable with the antitumor agent camptothecin (100 mM). Compounds 4 and 8 also caused moderate inhibition of 27.3 and 15.7z, but others were shown to weakly inhibit. In terms of structure-activity relationships, no considerable functional groups were taken to show topo I inhibitory activity, but substitutions with electron-withdrawing groups containing halogens seem to potentiate the activity. In addition, with respect to topo II, the decatenation of KDNA was induced by topo II. Under these experimental conditions, most of the compounds tested at a concentration of 50 mg W ml were shown to be weak inhibitors (Table 2 ), but compounds 5 and 12 were found to be moderate inhibitors of the catalytic activity of topo II (Fig. 3A  and 3B ). No considerable functional groups were taken to show topo II inhibitory activity between the tested compounds. These results suggest that several active compounds showed relatively selective inhibitory activity against topoisomerase I compared to topoisomerase II. In view of the inhibitory activity of topo I or II by benz[f ]indole-4,9-dione analogs, the intercalating potential of an individual compound, because of the planar structure of compounds, might be one of the factors for the catalytic activity, and further study is needed to clarify the additional factors. No obvious correlation was observed between the cytotoxicity of the individual compound and the inhibitory activity of DNA relaxation and decatenation by topoisomerase I and II, respectively, in vitro. However, it is not plausible to exclude the possibility that diŠerences in compound-uptake into cells exist, or that compounds are metabolized or sequestered in diŠerent ways, or that other mechanisms of actions might be included.
In summary, new structural modiˆcations of benz[f ]indole-4,9-dione analogs were suggested for cytotoxic agents against human cancer cells, and some compounds inhibited the catalytic activity of topo I or II, but further study for the mechanism of action by the compounds might be needed.
